ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) and Hypermarcas (OTCMKTS:HYPMY – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Profitability
This table compares ANI Pharmaceuticals and Hypermarcas’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals | 11.07% | 27.37% | 10.47% |
| Hypermarcas | 19.77% | 12.68% | 6.78% |
Risk and Volatility
ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Hypermarcas has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ANI Pharmaceuticals | $883.37 million | 1.87 | $78.34 million | $4.64 | 15.52 |
| Hypermarcas | $1.38 billion | 1.99 | $213.10 million | $0.50 | 7.78 |
Hypermarcas has higher revenue and earnings than ANI Pharmaceuticals. Hypermarcas is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for ANI Pharmaceuticals and Hypermarcas, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANI Pharmaceuticals | 0 | 4 | 3 | 0 | 2.43 |
| Hypermarcas | 0 | 1 | 0 | 1 | 3.00 |
ANI Pharmaceuticals presently has a consensus price target of $99.60, indicating a potential upside of 38.33%. Given ANI Pharmaceuticals’ higher probable upside, equities analysts clearly believe ANI Pharmaceuticals is more favorable than Hypermarcas.
Institutional & Insider Ownership
76.0% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
ANI Pharmaceuticals beats Hypermarcas on 8 of the 15 factors compared between the two stocks.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
About Hypermarcas
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
